CombiGene celebrates International Epilepsy Day

The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International Epilepsy Day is for all the world’s epilepsy associations to jointly acknowledge and highlight the disease and its consequences. The day also includes coordinated information and education efforts to strengthen efforts worldwide for people with epilepsy.

International Epilepsy Day is a joint initiative between the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) as well as their representation in 138 countries. With both national epilepsy federations and medical profession in close cooperation, alongside with cooperation with WHO and with IBE’s consultative status in the UN ECOSOC, International Epilepsy Day is the most prestigious epilepsy activity in the world.

For more information, see: https://internationalepilepsyday.org/

Source Svenska Epilepsiförbundet: 

CombiGenes Karin Agerman talks about the possibilities of gene therapy at the Swedish Epilepsy Association’s webinar on 8 February
CombiGene is a Swedish gene therapy company that develops a gene therapeutic treatment for epilepsy. This development project is in a late preclinical phase with the first human study scheduled for 2022. Karin Agerman, CombiGene’s Chief Research & Development Officer has been invited to speak under the heading Is gene therapy the future of treatment for epilepsy?

Information about the Swedish Epilepsy Association’s webinar
Link to Webinar:

Share